How much of the strong patient growth is due to the sales revamp versus organic factors, and if further acceleration is expected.

Growth is entirely organic, driven by two main factors: finding and training new reps effectively, and improved patient compliance initiatives by RTs, leading to better patient retention and longer billing periods. Both are expected to continue contributing. “It's all organic in terms of the complex respiratory growth with VENT and really sleep as well. But it's twofold. It's finding new reps. It's making sure that these reps are trained properly and up to speed a whole lot sooner rather than later.”

Which of the two segments (resupply vs. maternal health) is expected to drive more outsized growth and influence guidance adjustments.

Maternal health is expected to grow at a faster percentage rate due to its newer status and expansion into new markets and contracts. However, sleep resupply has also significantly outpaced core ventilator rental revenue. Both are expected to see significant growth, contributing to the changing financial profile. “Yes, clearly from a percentage basis, maternal is expected to grow at a faster percentage than the sleep resupply, but that's not discounting how much the resupply growth has outpaced the core ventilator rental revenue.”

Whether the Q2 increase in ventilator patient count (500+ net additions) was partly due to insurers approving previously denied patients following NCD changes.

The increase is partly due to insurers approving previously denied patients, as formulary rules now allow onboarding more patients within MA plans or private insurance. However, new orders, effective sales, and compliance initiatives are also major contributors. “Yes, that makes up part of it. Obviously, I would say if you think about how to rank these, just the new orders coming through makes up the largest piece. And undoubtedly, having formulary rules has given us the ability to onboard more patients within the MA plans or the private insurance plans.”

VMD

Viemed Healthcare (VMD) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

Viemed Healthcare Q2 FY26 — Record Revenue and Ventilator Patient Growth

Viemed Healthcare delivered record Q2 FY26 revenue driven by strong organic growth across its ventilator, sleep therapy, and maternal health segments. The company successfully adapted to new CMS National Coverage Determination requirements, achieving its highest-ever active ventilator patient count. While profitability was impacted by revenue mix and strategic investments in scaling operations, management remains confident in its diversified growth strategy and financial capacity for continued investment.

Highlights

Record quarterly revenue of $78.1 million, increasing approximately 24% from the prior year.
Highest active ventilator patient count in company history, reaching 12,635, with 546 net additions in Q2 (4.5% sequential growth).
Record quarter for PAP setups, with sleep therapy patients increasing 5% sequentially and 44% year-over-year.
Resupply patients served increased approximately 10% sequentially and 47% year-over-year.
Maternal health breast pump deliveries reached a new quarterly high, increasing approximately 9% sequentially.

Concerns

Adjusted EBITDA margin declined to 17.6% from 22.7% in the prior year quarter, influenced by revenue mix and temporary maternal health costs.
SG&A increased due to compensation for higher patient setup activity, phantom stock revaluations, technology investments, and temporary cost duplication.
Full-year adjusted EBITDA guidance revised slightly downwards to $64 million-$68 million from the previous range of $65 million-$69 million.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year net revenue	$314 million to $320 million high materiality	FY26	High
Full-year adjusted EBITDA	$64 million to $68 million high materiality	FY26	Medium
Full-year net CapEx as % of revenue	8.5% and 10% medium materiality	FY26	High
Full-year adjusted EBITDA margin	at least 20% high materiality	FY26	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Ventilator Rental Represented approximately 47% of total revenue, compared with approximately 54% in the prior year quarter.	$36.4M	8%	—	—
Other Rental	$16.4M	19%	—	—
Equipment Sales Growth across sleep-free supply and the maternal health business lines.	$19M	nearly doubled	—	—
Service	$6.3M	7%	—	—

Deals & partnerships

Lehan Acquisition of maternal health business.

Connects proven capability to Viemed's payer relationships, referral channels, and operating infrastructure to accelerate growth.

Risks & headwinds

Adjusted EBITDA margin pressure due to revenue mix shift and temporary costs Q2 FY26, expected to ease in H2 FY26

Adjusted EBITDA margin of 17.6% in Q2 FY26, down from 22.7% in Q2 FY25.

Mitigation:Diversifying into less capital-intensive product/service revenue lines (sleep resupply, maternal health) which have lower EBITDA but higher net income margins. Implementing new distribution capabilities, intake workflows, and in-house call centers to drive scalability and efficiency, reducing cost duplication.

Increased SG&A expenses from strategic investments Q2 FY26

SG&A increased, driven by compensation for higher patient setup activity, phantom stock revaluations, technology investments, and temporary duplication of costs.

Mitigation:These are deliberate decisions to support continued organic growth and expand product/service offerings. Investments in technology (e.g., Tenor intake workflow) are already showing increased productivity and capacity without proportional increases in fulfillment infrastructure.

What to watch in Q3 FY26

Adjusted EBITDA margin

H2 FY26

Current 17.6% in Q2 FY26

Target Improvement towards 20% full-year target, with H2 margins in line with prior year's 23%.

Why it matters

Indicates the effectiveness of strategic investments and operational efficiencies in offsetting revenue mix shifts and temporary costs.

The first half always carries a lower margin. just due to the patient holds and just the cost structure. It's the way it works through. With that said, we are clearly diversifying the company and changing the revenue composition of the company. And we are perfectly okay with that in that if it has a structurally lower EBITDA margin with no capex, coming from the sleep resupply and maternal business lines, net income margins are going to ultimately expand as a result of that.

Find out whether VMD delivers this. Inve re-checks your case every morning.

Q&A highlights

Details on the sales reorg, including leadership roles, boots on the ground, and ramp-up time for new hires.

The company added a fourth sales division, creating more leadership roles and geographic expansion opportunities. This allows for a clearer corporate ladder and improved training for new reps, who are now ramping up faster. The reorg is an ongoing process to support growth.

“we went through a big reorg last year. We intend to probably go through another one next year just because of the way that we're growing. It's something that's always happening and always evolving.”

asked by David Storms · answered by Casey Hoyt

2 min read 5 chapters

Detailed narrative

Ventilator Business Resilience and Growth

Despite the implementation of new CMS National Coverage Determination (NCD) for Home Mechanical Ventilation, Viemed achieved its highest active ventilator patient count in history, reaching 12,635 patients by the end of June. The company added 546 net ventilator patients during Q2, representing approximately 4.5% sequential growth.

This growth was supported by the second highest quarterly ventilator setup volume in company history and an improvement in usage compliance by over 25% compared to the prior year, demonstrating successful adaptation to the new NCD framework.

Diversified Expansion Across Service Lines

Beyond its core ventilation business, Viemed reported strong growth across other service lines. Q2 was a record quarter for PAP setups, with sleep therapy patients increasing approximately 5% sequentially and 44% year-over-year. Resupply patients served also saw significant growth, up approximately 10% sequentially and 47% year-over-year.

The maternal health segment, benefiting from the Lehan acquisition, reached a new quarterly high for breast pump deliveries, with activity increasing approximately 9% sequentially.

Strategic Investments in Operational Efficiency and Sales

Viemed made deliberate investments to support continued organic growth and scale its operations. This included a revamp of the sales organization, adding a fourth division and refining leadership roles to enhance market coverage and clinical support. Operationally, the company implemented a new intake workflow partner, Tenor, which reduced PAP order qualification review time from days to less than an hour and shortened the incomplete order pipeline time by several days.

The sleep resupply call center was also brought in-house to improve scalability.

Financial Performance and Capital Allocation

The company reported record revenue of $78.1 million in Q2, a 24% increase year-over-year. Gross profit was $45 million, representing a margin of 57.7%. Adjusted EBITDA was $13.7 million, with a margin of 17.6%, impacted by revenue mix and temporary maternal health costs.

Operating cash flow for the quarter was $15.9 million, and free cash flow was $8.6 million. Viemed repaid $2.2 million of debt and repurchased 531,000 shares for $5.1 million, ending June with $10.7 million in cash.

Outlook and Confidence in Future Growth

Management expressed increased confidence in full-year revenue, raising the low end of guidance to $314 million-$320 million. The net CapEx outlook was lowered to 8.5%-10% of revenue, reflecting the growing contribution from less capital-intensive product and service revenue. While full-year adjusted EBITDA guidance was slightly revised to $64 million-$68 million, the company expects to deliver a full-year adjusted EBITDA margin of at least 20% and generate solid free cash flow, funding continued growth across its diversified platform.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.